Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  1. Outputs

Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders

Academic Article
Publication Date:
2024
Short description:
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders / Oertel, F. C.; Zimmermann, H. G.; Motamedi, S.; Bereuter, C.; Manthey, L. M.; Ashtari, F.; Kafieh, R.; Dehghani, A.; Pourazizi, M.; Pandit, L.; D'Cunha, A.; Aktas, O.; Albrecht, P.; Ringelstein, M.; Martinez-Lapiscina, E. H.; Sanchez Dalmau, B. F.; Villoslada, P.; Asgari, N.; Marignier, R.; Cobo-Calvo, A.; Leocani, L.; Pisa, M.; Radaelli, M.; Palace, J.; Roca-Fernandez, A.; Leite, M. I. S.; Sharma, S.; De Seze, J.; Senger, T.; Yeaman, M. R.; Smith, T. J.; Cook, L. J.; Brandt, A. U.; Paul, F.. - In: NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION. - ISSN 2332-7812. - 11:5(2024). [10.1212/NXI.0000000000200273]
abstract:
Background and ObjectivesTo systematically describe the clinical picture of double-Antibody seronegative neuromyelitis optica spectrum disorders (DN-NMOSD) with specific emphasis on retinal involvement.MethodsCross-sectional data of 25 people with DN-NMOSD (48 eyes) with and without a history of optic neuritis (ON) were included in this study along with data from 25 people with aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD, 46 eyes) and from 25 healthy controls (HCs, 49 eyes) for comparison. All groups were matched for age and sex and included from the collaborative retrospective study of retinal optical coherence tomography (OCT) in neuromyelitis optica (CROCTINO). Participants underwent OCT with central postprocessing and local neurologic examination and antibody testing. Retinal neurodegeneration was quantified as peripapillary retinal nerve fiber layer thickness (pRNFL) and combined ganglion cell and inner plexiform layer thickness (GCIPL).ResultsThis DN-NMOSD cohort had a history of [median (inter-quartile range)] 6 (5; 9) attacks within their 5 ± 4 years since onset. Myelitis and ON were the most common attack types. In DN-NMOSD eyes after ON, pRNFL (p < 0.001) and GCIPL (p = 0.023) were thinner compared with eyes of HCs. Even after only one ON episode, DN-NMOSD eyes already had considerable neuroaxonal loss compared with HCs. In DN-NMOSD eyes without a history of ON, pRNFL (p = 0.027) and GCIPL (p = 0.022) were also reduced compared with eyes of HCs. However, there was no difference in pRNFL and GCIPL between DN-NMOSD and AQP4-NMOSD for the whole group and for subsets with a history of ON and without a history of ON-as well as between variances of retinal layer thicknesses.DiscussionDN-NMOSD is characterized by severe retinal damage after ON and attack-independent retinal neurodegeneration. Most of the damage occurs during the first ON episode, which highlights the need for better diagnostic markers in DN-NMOSD to facilitate an earlier diagnosis as well as for effective and early treatments. In this study, people with DN-NMOSD presented with homogeneous clinical and imaging findings potentially suggesting a common retinal pathology in these patients.
Iris type:
1.1 Articolo in rivista
List of contributors:
Oertel, F. C.; Zimmermann, H. G.; Motamedi, S.; Bereuter, C.; Manthey, L. M.; Ashtari, F.; Kafieh, R.; Dehghani, A.; Pourazizi, M.; Pandit, L.; D'Cunha, A.; Aktas, O.; Albrecht, P.; Ringelstein, M.; Martinez-Lapiscina, E. H.; Sanchez Dalmau, B. F.; Villoslada, P.; Asgari, N.; Marignier, R.; Cobo-Calvo, A.; Leocani, L.; Pisa, M.; Radaelli, M.; Palace, J.; Roca-Fernandez, A.; Leite, M. I. S.; Sharma, S.; De Seze, J.; Senger, T.; Yeaman, M. R.; Smith, T. J.; Cook, L. J.; Brandt, A. U.; Paul, F.
Authors of the University:
LEOCANI ANNUNZIATA MARIA LETIZIA
Handle:
https://iris.unisr.it/handle/20.500.11768/197798
Published in:
NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION
Journal
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.5.0.0